Tracer kinetic and biodistribution comparison of 11C-erlotinib, 18F-afatinib and 11C-osimertinib showed that 11C-erlotinib and 18F-afatinib had the highest tumor-to-lung contrast in EGFR mutated tumors. The gene discussed is EGFR; the disease is neoplasm.